- South Korea
- /
- Insurance
- /
- KOSE:A003690
There's No Escaping Korean Reinsurance Company's (KRX:003690) Muted Earnings
When close to half the companies in Korea have price-to-earnings ratios (or "P/E's") above 14x, you may consider Korean Reinsurance Company (KRX:003690) as a highly attractive investment with its 6.2x P/E ratio. However, the P/E might be quite low for a reason and it requires further investigation to determine if it's justified.
Recent times have been advantageous for Korean Reinsurance as its earnings have been rising faster than most other companies. One possibility is that the P/E is low because investors think this strong earnings performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.
Check out our latest analysis for Korean Reinsurance
What Are Growth Metrics Telling Us About The Low P/E?
In order to justify its P/E ratio, Korean Reinsurance would need to produce anemic growth that's substantially trailing the market.
Taking a look back first, we see that the company grew earnings per share by an impressive 47% last year. The latest three year period has also seen an excellent 142% overall rise in EPS, aided by its short-term performance. Accordingly, shareholders would have probably welcomed those medium-term rates of earnings growth.
Looking ahead now, EPS is anticipated to climb by 1.6% each year during the coming three years according to the four analysts following the company. Meanwhile, the rest of the market is forecast to expand by 17% per year, which is noticeably more attractive.
In light of this, it's understandable that Korean Reinsurance's P/E sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.
The Key Takeaway
Typically, we'd caution against reading too much into price-to-earnings ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
We've established that Korean Reinsurance maintains its low P/E on the weakness of its forecast growth being lower than the wider market, as expected. At this stage investors feel the potential for an improvement in earnings isn't great enough to justify a higher P/E ratio. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Many other vital risk factors can be found on the company's balance sheet. Take a look at our free balance sheet analysis for Korean Reinsurance with six simple checks on some of these key factors.
Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with a strong growth track record, trading on a low P/E.
Valuation is complex, but we're here to simplify it.
Discover if Korean Reinsurance might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSE:A003690
Korean Reinsurance
A reinsurance company, provides life and non-life reinsurance products in Korea and internationally.
Flawless balance sheet, undervalued and pays a dividend.
Similar Companies
Market Insights
Weekly Picks

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

AST SpaceMobile: The Boldest Direct-to-Cell Bet in Public Markets
Onto Innovation: The Advanced Packaging Chokepoint 51.3% undervalued intrinsic discount

Investment Analysis (May 2026)
Recently Updated Narratives

IonQ and Major Players Eyeing a $118.69 Fair Value Amid Quantum Growth

GoGold Resources, US$262M Cash Beats Los Ricos South Capex, Silver Giant Ready to be Built
Oracle: The AI Capex Spree Is Consuming the Cash Machine
Popular Narratives

Investment Analysis (May 2026)

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Honeywell - The Demand-Side of the AI Infrastructure
Trending Discussion
It's wonderful. It has greatly helped me take informed decisions.
